home.aspx
 
. https://www.drugpatentwatch.com/blog/valuation-of-pharma-companies-5-key-considerations/
blog article
VALUATION OF PHARMA COMPANIES: 5 KEY CONSIDERATIONS
Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. The life cycle of prescription drugs is relatively brief, with high-margin revenue falling to zero almost overnight when drug patents expire. Pharmaceuticals are high-growth, high-profit, and high-risk. Furthermore, the drug development pipeline is important enough that companies with little to no revenue may nonetheless be worth billions of dollars. Though there is no single “right” way to value pharma companies to inform investment or acquisition, there are several key factors worth examining. READ MORE